Cohance Lifesciences Limited (NSE:COHANCE)

India · Delayed Price · Currency is INR

324.50

+15.75 (5.10%)

Feb 18, 2026, 3:29 PM IST

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	Mar '19 Mar 31, 2019
Contract Development and Manufacturing Operations (CDMO)	11.98B	10.51B	13.40B		10.10B	8.34B
Contract Development and Manufacturing Operations (CDMO) Growth	13.91%	-21.56%	-		21.10%	-8.05%
Total	11.98B	10.51B	13.40B		10.10B	8.34B
Total Growth	13.91%	-21.56%	-		21.10%	-8.05%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	Mar '19 Mar 31, 2019
USA	2.55B	1.48B	833.90M		717.54M	502.06M
USA Growth	72.49%	77.17%	-		42.92%	33.82%
Europe	7.59B	7.36B	11.62B		8.27B	6.56B
Europe Growth	3.04%	-36.63%	-		26.12%	7.60%
India	749.80M	964.40M	259.34M		430.78M	395.23M
India Growth	-22.25%	271.87%	-		8.99%	-12.94%
Rest of The World	838.80M	536.50M	600.13M		678.65M	883.12M
Rest of The World Growth	56.35%	-10.60%	-		-23.15%	-58.82%
Total	11.72B	10.34B	13.31B		10.10B	8.34B
Total Growth	13.37%	-22.32%	-		21.10%	-8.05%

Source: S&P Global Market Intelligence.